Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

NCT07716046 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer
Hormone Receptor-positive Breast Cancer
HR+/HER2+ Breast Cancer

Interventions

DRUG: Fulvestaciclib
BIOLOGICAL: Trastuzumab
BIOLOGICAL: Pertuzumab
DRUG: Fulvestrant
DRUG: Letrozole
DRUG: Anastrozole
DRUG: Taxane

Sponsor

Fudan University

Collaborators

[object Object]